✦ LIBER ✦

Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma

✍ Scribed by John K. Chan; Michael R. Manuel; Giuseppe Ciaravino; Michael K. Cheung; Amreen Husain; Nelson N.H. Teng

Book ID: 113960673
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 184 KB
Volume: 103
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2006.05.035

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and efficacy of lenalidomide (Rev

Safety and efficacy of lenalidomide (Revlimid®) in recurrent ovarian and primary peritoneal carcinoma

✍ Mallory M. Zhang; John K. Chan; Amreen Husain; Hong-Yan Guo; Nelson N.H. Teng 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 129 KB

Efficacy and toxicity of weekly topoteca

Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer

✍ Tamar Safra; Joseph Menczer; Rinat Bernstein; Shulem Shpigel; Moshe J. Inbar; Da 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 223 KB

The Safety and Efficacy of Laparoscopic

The Safety and Efficacy of Laparoscopic Surgical Staging and Debulking of Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

✍ Nezhat, F.R.; DeNoble, S.M.; Brown, D.N.; Soto, E.; Liu, C.S.; Cho, J.E.; Chuang 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 38 KB

The safety and efficacy of cisplatin plu

The safety and efficacy of cisplatin plus gemcitabine in recurrent ovarian cancer

✍ Yui Tomita, Toshiaki Saito, Masao Okadome, Takako Eto, Kazuya Ariyoshi, Kumi Shi 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 189 KB

A prospective randomized trial of thalid

A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma

✍ Levi S. Downs Jr.; Patricia L. Judson; Peter A. Argenta; Rahel Ghebre; Melissa A 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB

## Abstract ## BACKGROUND. Thalidomide is an antiangiogenic agent with immune modulating potential. The objective of this study was to determine response rates among women who were treated for recurrent ovarian cancer using topotecan with or without thalidomide. ## METHODS. Women were enrolled i

KLK6 and KLK13 predict tumor recurrence

KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma

✍ White, N M A; Mathews, M; Yousef, G M; Prizada, A; Popadiuk, C; Doré, J J E 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 457 KB